| |
Subscription-based business models are vital for successful direct-to-consumer (DTC) testing. Discover the ins and outs of DTC testing and how to outlast the competition in this free guide. Download Now. 
|
|
Today's Big NewsJan 9, 2023 |
|
March 14-15, 2023 | San Francisco, CA Gain valuable insight from cross-functional team members responsible for search and evaluation, legal/IP, portfolio management, strategic alliances, business development and licensing. Register today to secure our lowest rates! 
|
|
| By Annalee Armstrong Editas is taking the red pen to its pipeline after a tough 2022 that saw the gene editing biotech cut a lead asset due to disappointing data—and the changes are going to mean more than a little rewrite. |
|
|
|
By Annalee Armstrong The markets battered biotechs in 2022, even those that had the backing of Moderna's venture capital firm Flagship Pioneering. But good science takes time, CEO Noubar Afeyan wrote in a letter to shareholders. |
By Nick Paul Taylor Johnston Erwin has persuaded some old friends to up their bet on TRexBio. Twenty months after taking over as CEO of the biotech, the Eli Lilly veteran has landed a deal with his former employer that sees the trade of $55 million for exclusive rights to three regulatory T-cell programs. |
Sponsored by Personalis Advanced ctDNA analysis yields biomarkers of cancer dynamics essential in therapeutic monitoring & intervention. Learn how NeXT Personal® detects MRD, monitors variants, & delivers powerful insights. |
|
Thursday, January 19, 2023 | 11:00am ET In this webinar, hear how Novartis uses social data from public forums worldwide to understand the educational and emotional needs of patients with Myelodysplastic Syndromes (MDS), and thereby create more targeted solutions to meet these needs. Register now. 
|
|
By Nick Paul Taylor AstraZeneca has kicked off the J.P.Morgan Healthcare Conference with a deal, capitalizing on the recent collapse of CinCor Pharma’s share price to snap up the blood pressure biotech in a $1.8 billion deal. |
By Annalee Armstrong Kronos Bio had a rough end to 2022, after having to toss away a late-stage acute myeloid leukemia asset. But 2023 is already looking a bit brighter, thanks to a new small molecule drug discovery pact with Roche’s Genentech. |
By James Waldron Boehringer Ingelheim wants to input its patient-derived T-cell receptor data into 3T Biosciences' platform with the hope of identifying new antigen targets for cancer immunotherapies. If successful, 3T could be in line for a $268 million payday. |
By James Waldron Novartis kept the faith in mavoglurant even after the therapy flunked a trial in a genetic disorder. Now, fellow Swiss drug developer Stalicla has signed off on $270 million in biobucks to take the asset into phase 3 for cocaine use. |
By James Waldron Voyager Therapeutics’ bet on its capsid technology continues to pay off, as the company banks $175 million from a strengthened collaboration with long-term partner Neurocrine Biosciences. |
By Annalee Armstrong Takeda and Arrowhead Pharmaceuticals have met at least one mark in a phase 2 study of a liver disease drug called fazirsiran, but placebo overperformed on reducing liver scarring, sending the biotech’s shares down over 22% Monday morning. Nevertheless, the partners are advancing the med to phase 3, albeit with a plan for a longer study period. |
By James Waldron,Annalee Armstrong,Nick Paul Taylor Join us for a rolling look at the top life sciences news coming out of this year's J.P. Morgan Healthcare Conference. |
By Annalee Armstrong Novavax CEO Stanley Erck is heading for retirement after 12 years at the helm, including the past three years in which he oversaw the company's transformation into a COVID-19 vaccine maker. |
By Max Bayer Astellas has inked two new licensing deals in the hopes of finding commercial success through external voyages, including a bolt-on deal with Selecta worth $350 million. |
By Ben Adams Pharvaris is looking for redemption for its leading hereditary angioedema (HAE) drug hopeful PHA121 in the form of a six-month animal toxicity trial aimed at assuaging concerns over the med’s safety. |
By Max Bayer A new year means new culls, and Annexon and Liminal are some of the first biotechs to shrink their clinical ambitions. |
By Annalee Armstrong Karuna Therapeutics is gearing up for a potential launch of schizophrenia med KarXT—one which analysts say could be “amongst the highest in profile in recent times.” But they’ll now be doing it without their Chief Commercial Officer Charmaine Lykins, who quietly departed Thursday afternoon. |
By James Waldron In a sign of BioNTech’s growing confidence and ambitions, the mRNA leader announced a deal struck directly with the U.K. government to recruit patients for trials of the German biotech’s cancer immunotherapies. |
By Helen Floersh Thanks to the success of Moderna and BioNTech’s COVID-19 vaccines, the question is no longer whether RNA technology can be put to use but where its limits lie. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we discuss the biotech industry’s rotten tomatoes. Plus, we cover the drug approvals of last year, a congressional report on Biogen's "inappropriate" communications with the FDA and other top headlines from this week. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 1:00pm ET This session will discuss key 2023 trends for healthcare and life sciences and how organizations should think about their data strategy and interoperability as they navigate the winds of change. Register now. 
|
|
Whitepaper This paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
